Skip to search formSkip to main contentSkip to account menu

Zankiren

Known as: (S)-N-((1S,2R,3S)-1-(Cyclohexylmethyl)-2,3-Dihydroxy-5-Methylhexyl)-Alpha((Alpha-S)-Alpha(((4-Methyl-1-Piperazinyl)Sulfonyl)Methyl)Hydrocinnamamido)-4-Thiazolepropionamide, 4-Thiazolepropanamide, N-(1-(Cyclohexylmethyl)-2,3-Dihydroxy-5-Methylhexyl)-Alpha-((2-(((4-Methyl-1-Piperazinyl)Sulfonyl)Methyl)-1-Oxo-3-Phenylpropyl)Amino)-, (1S-(1R*,(R*(R*)),2S*,3R*))- 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Elucidation of the binding mechanism of renin using a wide array of computational techniques and biological assays.
Review
2012
Review
2012
Aliskiren, the first direct renin inhibitor for treatment of hypertension: the path of its development.
Standard treatments available today for treating hypertension is diuretics, β-blockers, angiotensin converting enzyme inhibitors… 
Highly Cited
2005
Highly Cited
2005
Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats
Objectives Aliskiren is a new renin inhibitor of a novel structural class that has recently been shown to be efficacious in… 
1995
1995
Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects.
BACKGROUND Zankiren HCl (A-72517) is a potent renin inhibitor shown to have substantial bioavailability in several animal species… 
1995
1995
Renal vascular responses to renin inhibition with zankiren in men
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License